Formulation and Evaluation of Curcumin Loaded Nanoliposome on Brain Targeted
The present work aimed to produce Curcumin based nanoliposomes that nanoliposome can target the site via the brain in a controlled manner. Nanoliposomes are important in controlling the carriage; Curcumin which is an active constituent of curcuminoids thus also provides an effective treatment for the central nervous system and plays a crucial role. The interaction of the drug was ruled out by FT-IR studies and no incompatibility and lipids and surfactant. To optimize the formulation, factors affecting the physical appearance of Nanoliposomes were investigated. Curcumin-loaded Nanoliposomes were formulated using cholesterol by physical dispersion method and characterized for particle size, drug content, stability, production yield. Prepared nanoliposomes gave the better physical, morphological concerning the concentration of the lipids, surfactant, and ratio of lipid and surfactant. Six different formulations of Nanoliposomes F1-F6 were formulated to obtain the optimized formulation. The TEM (Transmission Electron Microscopy) of Nanoliposomes showed that they were rounded in shape and porous in texture. In-vitro drug release of formulation indicates that formulation F6 was selected as an optimized formulation for incorporation into the nanoliposomes among all the six formulations and liposome showed drug release in a controlled manner at the end of 10 hours.
2. Zhang HY, Tehranya EA, Kahn CJF, Ponc M¸ Lindera M, Cleymand F, (2012). Effects of nanoliposomes based on soya, rapeseed and fish lecithins on chitosan thin films designed for tissue Engineering. Carbohydrate Polymer 88, 618-627.
3. Shishu, Gupta N, Aggarwal N, (2008) Bioavailability enhancement and targeting of stomach tumors using gastro retentive floating drug delivery system of curcumin.
4. Yea T, Jiangb X, Li J, Yang R, Mao Y, Li L, (2015). Low molecular weight heparin mediating targeting of lymph nodemetastasis based on nanoliposome and enzyme- substrate interaction. Carbohydrate Polymer 122, 26-38.
5. Drummond DC, Noble CO, Guo Z, Hayes ME, Gabriel BS, Hann B, Development of a highly stable and targetable nanoliposomal formulation of topotecan. Journal of controlled released 141, 13-21.
6. Zucker D, Andriyanov AV, Steiner A, Raviv U, Barenholz Y, (2011). Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. Journal of Controlled Release 160, 281-289.
7. Mourtas S, Lazar AN, Eleni Markoutsa, Charles Duyckaerts, Sophia G. Antimisiaris (2014). Multifunctional nanoliposomes with curcuminelipid derivative and brain targeting functionality with potential applications for Alzheimer disease. European Journal of Medicinal Chemistry 80, 175-183.
8. Lazar AN, Mourtas S, Parizot C, Dauphin A, Delatour B, Antimisiaris SG, (2012). Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: Possible applications to Alzheimer disease. Nanomedicine : Nanotechnology, Biology, and Medicine 9, 712-721.
9. Sharma D, Nager N, Sing RP, Sharma AK (2011). Drug targeting to brain: a review. IJPRD/PUB/ARTI/VOV-3/ISSUE-1/MARCH/004.
10. Pardridge WM. Why is the global CNS pharmaceutical market so underpenetrated? Drug Discover. Today 7, 5–7 (2002).
11. Mozafari MR, Johnson C, Hatziantoniou S, Demetzos C, (2008).Nanoliposomes and Their Applications in Food Nanotechnology. Journal of liposome research, 18:309-327.
12. Zagana P, Haikou M, Klepetsanis P, Giannopoulou E, Ioannou PV, Antimisiaris, SG (2008). In vivo distribution of arsonoliposomes: effect of vesicle lipid composition. Int JPharm 347(1–2):86–92.
13 Siegel DP, Tenchov BG (2008). Influence of the lamellar phase unbinding energy on the relative stability of lamellar and inverted cubic phases. Biophys J 94:3987–3995.
14. Mozafari MR, Mortazavi SM (2005). Nanoliposomes: from Fundamentals to Recent Developments. Oxford, UK: Trafford Pub. Ltd.
15. Qiaoli G, Honggeng G, Qin S, Yanyun Z, Huilin Y (2015). Curcumin attenuated acute Propionibacterium acnes-induced liver injury through inhibition of HMGB1 expression in mice. International immunopharmacology 24, 159-165.
16. Pardridge WM (2003). Blood- brain barrier drug targeting: The future of brain drug development. Molecular interventions, volume3, Issue 2, 90-105.
17. Beevers SC, Huang S, (2011). Pharmacological and clinical properties of curcumin. Botanics: Targets and Therapy, 15-18.
18. Langer R. Polymer-Controlled Drug Delivery Systems. Acc Chem Res 1993; 26: 537- 542.
19. Kim J, Park K, Nam HY, Lee S, Kim K, Kwon IC. Polymers for bioimaging Progessive Polym Sci 2007; 32: 1031–1053.
20. Thacharodi D, Rao KP. Development and in vitro Evaluation of chitosan-based transdermal drug delivery systems for the controlled delivery of propranolol hydrochloride. Biomoterials 1995; 16: 145-148.
21. Davis SS, Illum L. Drug Delivery Systems for Challenging Molecules. Int J Pharm 1998; 176: 1-8.
22 Cross SE, Robert MS. Targeting local tissues by transdermal application: understanding drug physicochemical properties. Drug Develop Res 1999; 46: 309-315.
23. Finnin BC. Transdermal drug delivery- What to expect in the near future. Business briefing: Pharmatech 2003; 192-193.
24. Kumar R, Philip A. Modified Transdermal Technologies: Breaking the Barriers of Drug Permeation via the Skin. Trop J Pharm Res 2007; 6: 633-644.
25. Martin RJ, Denyer SP, Hadgraft J. Skin metabolism of topically applied compounds. Int J Pharm 1987; 39: 23-32.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.